COMMUNIQUÉS West-GlobeNewswire

Allscripts strengthens payer and life sciences’ focus and talent, expands capabilities
15/10/2018
Company brings together life science industry experts to accelerate growth and focus on Late-Phase Clinical Research, Real-World Evidence data and analytics solutions CHICAGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Today, [...]
Matinas BioPharma Appoints Global Pharmaceutical Drug Development Industry Leader Theresa Matkovits, Ph.D., Chief Development Officer; Further Expands Manufacturing and Clinical Development Team
15/10/2018
- Dr. Matkovits is an industry leader with 20+ years of proven global drug development success bringing 4 approved medicines to several global markets - - Frank Calamusa, CSCP, an established biotech CMC leader with 20 [...]
athenahealth Announces Third Quarter 2018 Earnings Conference Call
15/10/2018
WATERTOWN, Mass., Oct. 15, 2018 (GLOBE NEWSWIRE) -- athenahealth, Inc. (NASDAQ:ATHN), a leading provider of network-enabled services for hospital and ambulatory clients nationwide, today announced that it will hold a [...]
Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference
15/10/2018
NORCROSS, Ga., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that management will participate in the [...]
Daré Bioscience, Inc. to Present an Overview of Novel Intra-Vaginal Ring (IVR) Technologies at the Partnership Opportunities in Drug Delivery (PODD) Meeting Held in Boston, MA October 17th – 18th
15/10/2018
SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a clinical-stage, women’s health-focused biopharmaceutical company, today announced it will be presenting scientific and technical [...]
PetMed Express D/B/A 1-800-PetMeds to Announce its Second Quarter Financial Results on October 22, 2018
15/10/2018
DELRAY BEACH, Fla., Oct. 15, 2018 (GLOBE NEWSWIRE) -- PetMed Express, Inc. (NASDAQ: PETS) will announce its financial results for the quarter ended September 30, 2018 on Monday, October 22, 2018 at 8:00 A.M. Eastern [...]
Samumed Announces Sponsorship of Knee Osteoarthritis Registry Study
15/10/2018
Collaboration will prospectively evaluate the natural history of knee osteoarthritis progression SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today its sponsorship of a registry study in [...]
Rhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical Officer
15/10/2018
BOSTON, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic [...]
Sarepta and Lysogene Announce Exclusive License Agreement for LYS-SAF302, a Late-stage Gene Therapy for the Treatment of MPS IIIA, and Grant of Option Rights to an Additional CNS Gene Therapy Candidate
15/10/2018
-- Expands Sarepta’s portfolio to as many as 14 gene therapy programs -- -- Mucopolysaccharidosis type IIIA (MPS IIIA), also called Sanfilippo syndrome type A, is a rare, severe and fatal inherited neurodegenerative [...]
Mustang Bio Appoints Martina A. Sersch, M.D., Ph.D., as Chief Medical Officer
15/10/2018
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell ( [...]
Avalon GloboCare Announces Grand Opening of Newly Renovated Headquarters in New Jersey
15/10/2018
FREEHOLD, N.J., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today the grand opening of their newly renovated [...]
Inovio’s Ebola Vaccine Provides 100% Protection And Elicits Long-Lasting Immune Responses in Preclinical Studies
15/10/2018
Article in Journal of Infectious Diseases Supports Rationale For Inovio’s Ebola Vaccine Stockpile Program PLYMOUTH MEETING, Pa., Oct. 15, 2018 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced [...]
Extendicare Announces October 2018 Dividend of C$0.04 per Share
15/10/2018
MARKHAM, Ontario, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.04 per common share of the Company (the “Common [...]
IRIDEX Announces Appointment of Robert E. Grove, Ph.D. to its Board of Directors
15/10/2018
MOUNTAIN VIEW, Calif., Oct. 15, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX) today announced the appointment of Dr. Robert Grove to the Company’s Board of Directors effective October 15, 2018. Concurrently [...]
Savara Completes Enrollment in Pivotal Molgradex Impala Clinical Study for the Treatment of aPAP
15/10/2018
Top Line Results Expected in Q2 2019 AUSTIN, Texas, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced completion of the target enrollment of 135 patients in [...]
Tyme Appoints Former Kite and Celgene Executive, Michele Korfin, as Chief Commercial Officer
15/10/2018
NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies Inc, (Nasdaq: TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced the appointment [...]
CTD Holdings Announces Plans to Broaden its Expanded Access Program for Trappsol® Cyclo™
15/10/2018
Company expects to provide its drug to new patients in early 2019 ALACHUA, Fla., Oct. 15, 2018 (GLOBE NEWSWIRE) -- CTD Holdings, Inc. (OTCQB: CTDH), a clinical stage biotechnology company that develops cyclodextrin- [...]
Delcath Expands Rollout of Registration Trial in Metastatic Ocular Melanoma
15/10/2018
Seven Cancer Centers in United States Open for Enrollment in Amended Trial NEW YORK, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB: DCTH), an interventional oncology company focused on the treatment of [...]
Krystal Biotech Announces Positive Interim Results from Placebo-Controlled Phase 1/2 Clinical Trial of KB103
15/10/2018
KB103 is Krystal’s first "off-the-shelf", topical, gene therapy candidate to treat patients suffering from Dystrophic Epidermolysis Bullosa. Results on 2 patients met all primary efficacy (presence of functional COL7 [...]

Pages